Gain Therapeutics, Inc. (GANX)

Gain Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.06	0.13	0.13	-
Revenue Growth (YoY)	-	-58.40%	-0.96%	-	-
Cost of Revenue	10.65	11.38	8.24	7.16	2.26
Gross Profit	-10.65	-11.32	-8.11	-7.03	-2.26
Selling, General & Admin	9.71	10.93	9.68	6.84	1.25
Other Operating Expenses	-	-	-0.01	-0.03	-0.03
Operating Expenses	9.71	10.93	9.68	6.81	1.22
Operating Income	-20.36	-22.26	-17.79	-13.84	-3.48
Interest & Investment Income	0.37	0.5	0.39	0.02	0
Currency Exchange Gain (Loss)	0.12	-0.43	-0.1	-0.07	-0.1
Pretax Income	-19.87	-22.19	-17.5	-13.89	-3.57
Income Tax Expense	0.54	0.08	0.09	0	0.01
Net Income	-20.41	-22.27	-17.59	-13.89	-3.58
Net Income to Common	-20.41	-22.27	-17.59	-13.89	-3.58
Shares Outstanding (Basic)	23	13	12	10	3
Shares Outstanding (Diluted)	23	13	12	10	3
Shares Change (YoY)	75.86%	9.49%	16.90%	279.11%	19.17%
EPS (Basic)	-0.89	-1.71	-1.48	-1.37	-1.33
EPS (Diluted)	-0.89	-1.71	-1.48	-1.37	-1.33
Free Cash Flow	-18.9	-18.88	-14.81	-12.46	-3.26
Free Cash Flow Per Share	-0.83	-1.45	-1.25	-1.23	-1.22
Operating Margin	-	-40336.86%	-13410.18%	-10332.05%	-
Profit Margin	-	-40354.33%	-13262.02%	-10371.70%	-
Free Cash Flow Margin	-	-34217.53%	-11166.38%	-9303.42%	-
EBITDA	-20.32	-22.22	-17.76	-13.82	-3.47
D&A For EBITDA	0.04	0.04	0.03	0.02	0.01
EBIT	-20.36	-22.26	-17.79	-13.84	-3.48
Revenue as Reported	-	0.06	0.14	0.16	0.03

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q